PMID- 28743539
OWN - NLM
STAT- MEDLINE
DCOM- 20181029
LR  - 20181029
IS  - 0210-5705 (Print)
IS  - 0210-5705 (Linking)
VI  - 40
IP  - 9
DP  - 2017 Nov
TI  - Recommendations of everolimus use in liver transplant.
PG  - 629-640
LID - S0210-5705(17)30131-0 [pii]
LID - 10.1016/j.gastrohep.2017.05.008 [doi]
AB  - Mammalian target of rapamycin (mTOR) inhibitors, everolimus (EVL) and sirolimus 
      are immunosuppressive agents with a minor nephrotoxic effect, limited to the 
      development of proteinuria in some cases. The combination of EVL and low-dose 
      tacrolimus has proven to be as safe and effective as standard therapy with 
      tacrolimus for the prevention of acute cellular rejection. Early initiation of 
      EVL-based immunosuppressive regimens with reduced exposure to calcineurin 
      inhibitors has been shown to significantly improve renal function of LT 
      recipients during induction and maintenance phases, with comparable efficacy and 
      safety profiles. In patients with established kidney failure, initiating EVL may 
      enable clinicians to reduce calcineurin inhibitors exposure, thereby contributing 
      to the improved renal function of these patients. Although there is not 
      sufficient evidence to recommend their use to prevent the recurrence of 
      hepatocellular carcinoma and the progression of de novo tumours, they are used in 
      this context in routine clinical practice.
CI  - Copyright (c) 2017 Elsevier Espana, S.L.U., AEEH y AEG. All rights reserved.
FAU - Rubin Suarez, Angel
AU  - Rubin Suarez A
AD  - Unidad de Hepatologia, Servicio de Medicina Digestiva, Area de Enfermedades 
      Digestivas, Hospital Universitari i Politecnic La Fe, CIBERehd, Valencia, Espana. 
      Electronic address: rubin_ang@gva.es.
FAU - Bilbao Aguirre, Itxarone
AU  - Bilbao Aguirre I
AD  - Servicio de Cirugia HBP y Trasplantes Digestivos, Hospital Universitario Vall 
      d'Hebron. Grupos de investigacion VHIR y CIBERehd, Barcelona, Espana.
FAU - Fernandez-Castroagudin, Javier
AU  - Fernandez-Castroagudin J
AD  - Servicio de Medicina Digestiva, Hospital Clinico Universitario de Santiago de 
      Compostela, Santiago de Compostela, Espana.
FAU - Pons Minano, Jose Antonio
AU  - Pons Minano JA
AD  - Unidad de Hepatologia y Trasplante Hepatico, IMIB. Hospital Clinico Universitario 
      Virgen de la Arrixaca, Murcia, Espana.
FAU - Salcedo Plaza, Magdalena
AU  - Salcedo Plaza M
AD  - Unidad de Trasplante Hepatico, Servicio de Aparato Digestivo, Hospital General 
      Universitario Gregorio Maranon IISGM. CIBERehd, Madrid, Espana.
FAU - Varo Perez, Evaristo
AU  - Varo Perez E
AD  - Unidad de Trasplante Abdominal, Hospital Clinico Universitario de Santiago de 
      Compostela, Santiago de Compostela, Espana.
FAU - Prieto Castillo, Martin
AU  - Prieto Castillo M
AD  - Unidad de Hepatologia, Servicio de Medicina Digestiva, Area de Enfermedades 
      Digestivas, Hospital Universitari i Politecnic La Fe, CIBERehd, Valencia, Espana.
LA  - eng
LA  - spa
PT  - Journal Article
PT  - Review
TT  - Recomendaciones de uso de everolimus en el trasplante hepatico.
DEP - 20170723
PL  - Spain
TA  - Gastroenterol Hepatol
JT  - Gastroenterologia y hepatologia
JID - 8406671
RN  - 0 (Immunosuppressive Agents)
RN  - 9HW64Q8G6G (Everolimus)
SB  - IM
MH  - Everolimus/adverse effects/*therapeutic use
MH  - Graft Rejection/prevention & control
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects/*therapeutic use
MH  - Kidney Diseases/chemically induced/prevention & control
MH  - *Liver Transplantation
MH  - Postoperative Complications/chemically induced/prevention & control
MH  - Practice Guidelines as Topic
OTO - NOTNLM
OT  - Everolimus
OT  - Hepatocarcinoma
OT  - Hepatocellular carcinoma
OT  - Immunosuppression
OT  - Inmunosupresion
OT  - Insuficiencia renal
OT  - Liver transplantation
OT  - Nefrotoxicidad
OT  - Nephrotoxicity
OT  - Renal insufficiency
OT  - Sirolimus
OT  - Trasplante hepatico
EDAT- 2017/07/27 06:00
MHDA- 2018/10/30 06:00
CRDT- 2017/07/27 06:00
PHST- 2017/01/16 00:00 [received]
PHST- 2017/05/23 00:00 [revised]
PHST- 2017/05/23 00:00 [accepted]
PHST- 2017/07/27 06:00 [pubmed]
PHST- 2018/10/30 06:00 [medline]
PHST- 2017/07/27 06:00 [entrez]
AID - S0210-5705(17)30131-0 [pii]
AID - 10.1016/j.gastrohep.2017.05.008 [doi]
PST - ppublish
SO  - Gastroenterol Hepatol. 2017 Nov;40(9):629-640. doi: 
      10.1016/j.gastrohep.2017.05.008. Epub 2017 Jul 23.